Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
Titel:
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
Auteur:
Holch, J.W. Ricard, I. Stintzing, S. Fischer von Weikersthal, L. Decker, T. Kiani, A. Vehling-Kaiser, U. Heintges, T. Kahl, C. Kullmann, F. Scheithauer, W. Moehler, M. Jelas, I. Modest, D.P. Westphalen, C.B. von Einem, J.C. Michl, M. Heinemann, V.